RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Clinical trials for RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 20:11 UTC
-
New drug duo targets tough bladder cancers
Disease control OngoingThis early-stage trial is testing a combination of two targeted drugs, erdafitinib and enfortumab vedotin, for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The main goals are to find the safest and most effective dose of the drug…
Matched conditions: RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for tough bladder cancers: can a combo outsmart tumors?
Disease control OngoingThis study is for people with advanced bladder cancer that has spread or come back and cannot be treated with cisplatin. It is testing if adding a chemotherapy drug (eribulin) to an immunotherapy drug (atezolizumab) works better and is safe compared to using the immunotherapy alo…
Matched conditions: RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC